PhillyTablet Inquirer Daily News
philly.com
email
font size
comments
0
options
 
Wednesday, November 19, 2008

Tengion, an East Norriton-based company that makes medical organ-regeneration systems at its Winston-Salem, North Carolina, factory, says it's raised $21 million from locally-based Safeguard Scientifics Inc. and Quaker BioVentures, and from Bain Capital LLC, Johnson & Johnson Development Corp., Deerfield Partners, Health Cap, L Capital Partners, and Oak Investment Partners.

"There wasn't really a lead investor," said Tengion chief financial officer Gary Sender. "We're really glad to add Safeguard Scientifics to our private investors." Tengion has raised $140 million since 2004. Will it keep raising money, go public, or - like most biotechs lately - sell to a big company once its products get commercial? "We are open to all avenues to fund the company," said Sender. "Management's objective is to keep developing the technology and bring it to patients."

The new money will mostly pay for Phase 3 clinical trials for Tengion's Neo-Bladder Augment, which, Tengion says, uses "the body's own regenerative cells" to re-grow damaged human bladders.

Posted by Joseph N. DiStefano @ 8:58 AM  Permalink | Post a comment
Comments   


0 comments
About Joseph N. DiStefano
Joseph N. DiStefano writes this blog to feed his PhillyDeals column in the Philadelphia Inquirer. Joe has been a member of Bloomberg LP’s New York Finance Team, wrote the book “Comcasted,” taught writing at St. Joseph’s University, and studied economics and history at Penn. Reach Joe at 215-854-5194 and JoeD@phillynews.com